Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163-0001, USA.
Pharmacotherapy. 2010 Jun;30(6 Pt 2):35S-41S. doi: 10.1592/phco.30.pt2.35S.
An institution's formulary is a constantly evolving entity with a myriad of considerations that must be taken into account when any agent or chemical entity is being evaluated for formulary inclusion or is under review to continue as a therapeutic option. Originally a simple list of available agents, the formulary has developed into a required part of the hospital's administrative structure and an authoritative source for cost-effective management of drug use within the institution. In recent years, closer evaluations of internal processes surrounding drugs with black-box warnings, safety protocols, and the development of programs such as the risk evaluation and mitigation strategies (REMS) have added to the costs of using some therapeutic agents. Whether it is regulatory agencies levying fines for inappropriate use of a drug, the cost of compliance with various therapeutic protocols within an institution, or the costs of adhering to the requirements of REMS, formulary choices have a much greater impact on an institution's budget now than they did in the recent past. In the future, one may also see reduced or denied payments under increasingly recognized "never events," should they be applied specifically to a given drug or class of drugs. Forward-looking pharmacists must accept the challenge of making thoughtful formulary decisions within this complex milieu that extends well beyond assessment of cost-effectiveness focused on therapeutic efficacy and acquisition costs.
医疗机构的处方集是一个不断发展变化的实体,在评估任何药物或化学实体是否列入处方集或继续作为治疗选择时,必须考虑到无数因素。处方集最初只是一个可用药物的简单列表,现已发展成为医院管理结构的必要组成部分,也是在机构内管理药物使用成本效益的权威来源。近年来,对带有黑框警告、安全协议的药物以及风险评估和缓解策略 (REMS) 等计划的内部流程进行了更密切的评估,增加了使用某些治疗药物的成本。无论是监管机构因药物使用不当而罚款,还是机构内遵守各种治疗方案的合规成本,还是遵守 REMS 要求的成本,现在处方集的选择对机构预算的影响都比过去要大得多。在未来,随着越来越多的“不应发生事件”(never events)得到认可,处方集的选择也可能会减少或拒绝支付,具体情况取决于它们是否专门针对特定药物或某一类药物。有远见的药剂师必须在这一复杂环境中接受深思熟虑的处方集决策的挑战,这一环境远远超出了以治疗效果和采购成本为重点的成本效益评估。